The Allogeneic Cell Therapy Manufacturing Market is expected to grow at a 15.0 % CAGR during the forecast period for 2023-2031.
Key Industry Insights & Findings from the Report:
- The rise in chronic conditions such as cancer, autoimmune disorders, and cardiovascular diseases is a major driver.
- The expanding use of allogeneic cell therapies across a wide range of medical conditions, including dermatological, neurological, and musculoskeletal disorders, is opening new market opportunities.
- North America dominated the market and accounted for a global revenue share in 2023.
- The technical complexity of cell therapy manufacturing, including the need for highly specialized equipment and skilled personnel, presents ongoing challenges.
Allogeneic cell therapies involve the transfer of cells from a donor to a patient. Allogeneic cells are collected from various sources, among which blood is the prominent source for allogeneic cells. The small volume of blood comprises many cells that quickly gets multiply.
The key factors driving the growth of the allogeneic cell therapy manufacturing market include the rising elderly population, high prevalence of chronic diseases, the growing demand for personalized treatments, increasing healthcare expenditure, rapid technological advancements in the healthcare sector. Many biopharma companies are collaborating to improve research and development activities in stem cell research, considering the need for allogeneic cell therapies. Likely to propel the growth opportunities for the allogeneic cell therapy manufacturing market in the forthcoming years. For instance, in September 2021, Adaptimmune Therapeutics (UK) partnered with Roche Group member, Genentech, to develop and market allogeneic cell therapies to treat multiple cancer indications.
However, the expensive manufacturing of allogeneic cell therapies and the risks associated with allogeneic cell therapies may hamper the market growth over the forecast period.
Market Segmentation
The allogeneic cell therapy manufacturing market is classified based on products, scale of operation, and region. By products, the market Induced pluripotent stem cells (iPSC), T-cells and Natural killer (NK) cells, Human pluripotent stem cells (hPSCs), Mesenchymal stem cells (MSC), β-cells, Neurons, Immortalized and engineered cell lines, and Tissue engineered product. The mesenchymal stem cells (MSCS) segment is expected to hold the maximum market share in the coming days due to the increasing R&D activities in stem cell therapies. The market is classified Preclinical Scale Operations, Clinical Scale Operations, and Commercial Scale Operations in terms of scale of operation.
Regionally, the market is studied across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America is estimated to hold the maximum share of the market over the forecast years, followed by Europe owing to the growing patients of chronic diseases and surging R&D activities by key players to develop effective allogeneic cell therapies.
Recent Developments:
- In February 2024, The University of Wisconsin Madison strategically partners with Waisman Biomanufacturing, a leading contract development and manufacturing organization (CDMO), to announce a strategic partnership with RoosterBio, Inc., a leading supplier of human mesenchymal stem/stromal cells (MSCs), highly engineered media solutions, and bioprocess development services.
Competitive Landscape
Some Of The Key Players In The Allogeneic Cell Therapy Manufacturing Market:
- Lonza Group,
- KBI Biopharma, Inc.,
- Waisman Biomanufacturing,
- Cell and Gene Therapy Catapult,
- Thermo Fisher Scientific, Inc.,
- Merck KGaA,
- Catalent Inc.,
- Oxford Biomedica Plc,
- Fujifilm Cellular Dynamics, Inc.,
- Wuxi Apptec,
- Charles River Laboratories International, Inc.,
- The Discovery Labs LLC,
- ABL, Inc.,
- BioCentriq,
- Commercializing Living Therapies
The Allogeneic Cell Therapy Manufacturing Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 993.19 Million |
|
Revenue Forecast In 2031 |
USD 3643.57 Million |
|
Growth Rate CAGR |
CAGR of 15.7 % from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Products, By Scale of Operations |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Lonza Group, KBI Biopharma, Inc., Waisman Biomanufacturing, Cell and Gene Therapy Catapult, Thermo Fisher Scientific, Inc., Merck KGaA, Catalent Inc., Oxford Biomedica Plc, Fujifilm Cellular Dynamics, Inc., Wuxi Apptec, Charles River Laboratories International, Inc., The Discovery Labs LLC, ABL, Inc., BioCentriq, Commercializing Living Therapies, and others. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
